

# Agreement of treatment effects from non-randomized studies using causal modelling and randomized trials: a meta-epidemiological study

Hannah EWALD<sup>\*1,2</sup>; Aviv LADANIE<sup>1,2</sup>; Kimberly A. MC CORD<sup>1,2</sup>; Heiner C. BUCHER<sup>1,2</sup>; John P.A. IOANNIDIS<sup>3-7</sup>; Lars G. HEMKENS<sup>1,2</sup>

<sup>\*</sup> [Hannah.Ewald@usb.ch](mailto:Hannah.Ewald@usb.ch) <sup>1</sup> Basel Institute for Clinical Epidemiology and Biostatistics (ceb), University Hospital Basel, University of Basel, Basel, Switzerland <sup>2</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland <sup>3</sup> Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, USA <sup>4</sup> Meta-Research Innovation Center at Stanford (METRICS), Stanford School of Medicine, Palo Alto, USA <sup>5</sup> Department of Health Research and Policy, Stanford University School of Medicine, Stanford, USA <sup>6</sup> Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, USA <sup>7</sup> Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, USA

What is the agreement of treatment effects from non-randomized studies using causal modelling and from RCTs investigating the same clinical question?

## ELIGIBILITY

- Non-randomized studies using marginal structural models providing an effect estimate on any healthcare outcome
- RCTs on the same clinical question published before or after the non-randomized study

## ANALYSES

- Comparison of the direction of treatment effects, effect sizes, and confidence intervals
- Absolute deviation between study designs
- ROR: summary of ORs of treatment effects from RCTs divided by MSM-study effect estimates
- Combined the RORs of all clinical questions using random-effects meta-analysis
- Meta-regression was used to assess whether the agreement between study designs is associated with previous knowledge of RCT-effects.





Figure 2: Treatment effects estimated with non-randomized studies using marginal structural models and RCTs. Left panel: effect estimates (diamonds) and 95% confidence intervals (CIs) of 19 clinical questions reported in MSM-studies (lower graphs, orange) and in RCTs (upper graphs, green). Right panel: ratio of odds ratios (blue squares; lines: 95% CIs); combined summary ROR (diamond, random-effects meta-analysis). Values > 1 indicate more favorable results for the experimental treatment by non-randomized studies using causal modelling.

\* Studies focussing on statistical methodology

## RESULTS

- 19 non-randomized studies with 1,039,570 patients and 141 corresponding RCTs with 120,669 patients were included
- 124/141 RCTs (88%) were published before the non-randomized study
- 3/19 studies focused on statistical methodology, 16 on clinical decision making.
- 37% of non-randomized studies had opposite directions of effect estimates than RCTs (8/19 clinical questions)
- 47% of non-randomized studies' 95% confidence intervals did not include the RCT estimate (9/19 clinical questions)
- Non-randomised study effects deviated systematically by 1.29-fold (summary absolute deviation OR 1.29; 1.12 to 1.48)
- Overall, causal modelling studies tended to show more favorable results for the experimental treatment (sROR 1.14; 0.93 to 1.41), in particular when excluding studies focussing on statistical methodology (16 studies, sROR 1.34; 1.03 to 1.75), and when more RCTs were previously published (p=0.037).

## CONCLUSION AND TAKE HOME MESSAGE

- Treatment effects from non-randomized studies using causal modelling often deviate from RCTs on the same research question and may show stronger effects for experimental treatments.
- Remain cautious when using non-randomized "real world" evidence to guide your health care decisions – even when causal modelling techniques were applied and especially when no evidence from RCTs exists.

## FUNDING

This work was supported by the Gottfried and Julia Bangerter-Rhyner-Foundation. The Meta-Research Innovation Center at Stanford is funded by a grant by the Laura and John Arnold Foundation. The Basel Institute of Clinical Epidemiology and Biostatistics is supported by Stiftung Institut für klinische Epidemiologie.

## ABBREVIATIONS

MSM-Studies: non-randomized studies using marginal structural models; RCT: randomized controlled trial; ROR: ratio of odds ratios (ratio of outcome effects reported in non-randomized studies versus randomized trial evidence); sROR summary ratio of odds ratio